ARIA 2017: a Review of Major Changes and Innovations
Allergic rhinitis is a disease underestimated by patients, and underdiagnosed and thus undertreated by physicians since most of the patients present with symptoms of moderate-to-severe disease, overall diminished quality of life, impairing sleep quality and cognitive function, and a substantial impact on work productivity, school absenteeism, and costs. The relationship between treating physician and patients is crucial in all chronic diseases.
Review the main changes and innovations of recent years in the ARIA guidelines.
The most recent publications of the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were reviewed.
ARIA 2016 strengthens the role of patients in the control and treatment of their symptoms by the use of technology, which improves physician-patient communication. The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. It confirms that inhaled corticosteroids are the most effective drugs for the management of seasonal or perennial allergic rhinitis, not surpassed by combination therapies with oral or topical antihistamines. On the other hand, no significant differences between the use of oral or topical antihistamines are evidenced. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. A step-up/step-down individualized approach to AR pharmacotherapy might hold the potential for optimal control of AR symptoms while minimizing side effects and costs. After choosing the best pharmacological therapy, compliance is a critical issue in the management of all chronic diseases. In order to improve compliance, it is important to consider patient preferences and views of patients and their caregivers, as ARIA guidelines remarks in the 2016 update.
ARIA guideline has evolved to a technology-based implementation strategy to help rhinitis sufferers to have an active and healthy life and to reduce health and social inequalities caused by this very common disease, irrespective of their age, sex, or socio-economic status.
KeywordsARIA Rhinitis Pharmacological therapy Quality of life Emerging technologies
Compliance with Ethical Standards
Conflict of Interest
Dr. Neffen declares that he has no conflict of interest.
Dr. Ivancevich reports personal fees from Faes Farma, personal fees from Eurofarma, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 5.• Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8. https://doi.org/10.1016/j.jaci.2017.03.050. ARIA recommendations support patients, caregivers, and health care providers in choosing the optimal treatment.CrossRefPubMedGoogle Scholar
- 8.Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, et al. Scaling up strategies of the chronic respiratory disease programme of the European innovation partnership on active and healthy ageing (action plan B3: area 5). Clin Transl Allergy. 2016;6:29.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.• Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138:367–374.e2. A step-up/step-down individualized approach to allergic rhinitis pharmacotherapy might hold the potential for optimal control of symptoms while minimizing side effects and costs.CrossRefPubMedGoogle Scholar
- 10.• Bourret R, Bousquet J, Mercier J, Camuzat T, Bedbrook A, Demoly P, et al. MASKrhinitis: a single tool for integrated care pathways in allergic rhinitis. World Hosp Health Serv. 2015;51:36–9.MASK-rhinitis will be important for establishing care pathways across the life cycle, stratify patients with severe uncontrolled rhinitis and to perform clinical trials.PubMedGoogle Scholar
- 12.• Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47. ARIA has evolved from a rigorously developed guideline to a mobile technology-based implementation strategy in order to provide an active and healthy life to rhinitis sufferers.CrossRefPubMedPubMedCentralGoogle Scholar